Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study
Scandinavian Journal of Immunology · 2024
DOI: 10.1111/sji.13409 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Scandinavian Journal of Immunology, 2024. Verfasst von Laura Gregersen und 27 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Diagnostics and Clinical Research Unit, University Hospital of Southern Denmark, Aabenraa, Denmark. Hauptthemen laut MEDLINE: Glutens, Biological Products. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Foundation, Oak Foundation, Knud og Edith Eriksens Mindefond.
Abstract (Originalsprache)
Chronic inflammatory diseases (CIDs) pose a growing healthcare challenge, with a substantial proportion of patients showing inadequate response to biological treatment. There is renewed interest in dietary changes to optimize treatment regimens, with a growing body of evidence suggesting beneficial effects with adherence to a gluten‐free diet. This study compared the likelihood of achieving clinical response to biological treatment after 14–16 weeks in patients with CID with high versus low‐to‐medium gluten intake. Secondary outcomes of interest included changes in disease activity, health‐related quality of life and C‐reactive protein. The study was a multicentre prospective cohort of 193 participants with a CID diagnosis (i.e. Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis or Psoriasis) who initiated biological treatment between 2017 and 2020. Participants were stratified based on their habitual gluten intake: the upper 33.3% (high gluten intake) and the remaining 66.6% (low‐to‐medium gluten intake). The proportion of patients achieving clinical response to biological treatment after 14–16 weeks was compared using logistic regression models. The median gluten intake differed significantly between groups (12.5 g/day vs. 5.9 g/day, standardized mean difference = 1.399). In total, 108 (56%) achieved clinical response to treatment, with no difference between 35 (55%) in the high gluten group and 73 (57%) in the medium‐to‐low gluten group (OR = 0.96 [0.51–1.79], p = 0.897). No differences were found with secondary outcomes. In conclusion, this study found no association between gluten intake and response to biological treatment in patients with CID.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Diagnostics and Clinical Research Unit, University Hospital of Southern Denmark, Aabenraa, Denmark.
- The Faculty of Health Sciences, Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
- Research Unit of Gastroenterology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University Hospital of Southern Denmark, Aabenraa, Denmark.
- Open Patient Data Exploration Network (OPEN), Odense, Denmark.
ORCID-Profile: Laura Gregersen, Heidi Lausten Munk
Förderung
- Horizon Foundation
- Oak Foundation
- Knud og Edith Eriksens Mindefond
- Region Syddanmark
Zitieren
APA
Gregersen, L., Jessen, P. D., Lund, H. W., Overgaard, S. H., Hikmat, Z., Ellingsen, T., Kjeldsen, J., Pedersen, A. K., Petersen, S. R., Jawhara, M., Nexøe, A. B., Bygum, A., Hvas, C. L., Dahlerup, J. F., Bergenheim, F. O., Glerup, H., Henriksen, R. H., Guldmann, T., Hvid, L., …, & Andersen, V. (2024). Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13409
Vancouver
Gregersen L, Jessen PD, Lund HW, Overgaard SH, Hikmat Z, Ellingsen T, et al. Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study. Scandinavian Journal of Immunology. 2024. doi:10.1111/sji.13409
BibTeX
@article{Gregersen2024,
author = {Gregersen, Laura and Jessen, Pernille Dyhre and Lund, Helene Wiencke and Overgaard, Silja Hvid and Hikmat, Zainab and Ellingsen, Torkell and Kjeldsen, Jens and Pedersen, Andreas Kristian and Petersen, Sofie Ronja and Jawhara, Mohamad and Nexøe, Anders Bathum and Bygum, Anette and Hvas, Christian Lodberg and Dahlerup, Jens Frederik and Bergenheim, Frederik Olof and Glerup, Henning and Henriksen, Rikke Holm and Guldmann, Tanja and Hvid, Lone and Brodersen, Jacob and Munk, Heidi Lausten and Pedersen, Natalia and Saboori, Sanaz and Nielsen, Ole Haagen and Heitmann, Berit Lillenthal and Haldorsson, Thorhallur Ingi and Christensen, Robin and Andersen, Vibeke},
title = {Impact of gluten intake on clinical outcomes in patients with chronic inflammatory diseases initiating biologics: Secondary analysis of the prospective multicentre BELIEVE cohort study},
journal = {Scandinavian Journal of Immunology},
year = {2024},
doi = {10.1111/sji.13409}
}
EUVIMED